Article
Brochure
Executive Resource
Insight Hub
Video
Ext. Publication
Home /
Insights & Resources
Insights & Resources
Start exploring insights from across the industries we serve, featuring the latest industry trends, compliance alerts, tax and accounting news and much more.
- Alternative Investments
- Banking
- Blockchain & Digital Assets
- Construction
- Consumer Products
- Energy Transition
- Financial Services
- Food & Beverage
- General Business
- Government
- Health Care
- Higher Education
- Hospitality & Entertainment
- Industrial Products
- Insurance
- Life Sciences
- Not-for-Profit
- Oil & Gas
- Oilfield Services
- Real Estate
- Renewable Fuels
- Technology
- Transportation & Logistics
- Accounting Advisory
- Artificial Intelligence
- Asset Management Consulting
- Asset Tracing
- Cybersecurity
- Data Privacy
- Digital Transformation
- Energy Compliance
- Executive & Leadership Coaching
- Family Law
- Forensics & Litigation
- Government Consulting
- Health Care Valuation
- IT Advisory
- Risk Advisory
- Sustainability Consulting
- Transaction Advisory
- Trust & Estate
- Valuation
Private companies can simplify ASC 805 reporting for goodwill and intangibles. Explore ASU 2014-18 and 2014-02 alternatives, eligibility and key tips.
Is your transaction a business combination or asset acquisition? Learn how ASC 805 guidance, the screen test and key differences shape reporting.
Texas life sciences in 2025 saw concentrated capital, declining innovation output and earlier‑stage clinical shifts shaping the ecosystem.
Texas life sciences saw record capital in Q4 2025, even as innovation, early-stage funding and late-phase clinical trials continued to decline.
Weaver’s professionals discuss tax legislation and economic trends. Tips for audit and SOX compliance, M&A accounting as well as system implementations.
Executive ResourceBoard members might consider how recent government activity, climate considerations and supply chain vulnerabilities will affect their businesses.
J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.
The Q3 2024 Medtech Report from J.P. Morgan spotlights heightened investments, mergers and public offerings, signaling a positive industry outlook.
Weaver’s overview of the SEC’s 2025 examination priorities describe practices by investment advisers and others that may come under SEC review.
Weaver professionals discuss the U.S. Supreme Court’s decision to overturn the Chevron doctrine, cybersecurity and accounting reminders on goodwill impairment.
Boards and management may want to consider how recent Fed activity, election uncertainty, and emerging ERP considerations will affect their businesses.
Weaver’s second quarterly Accounting and SEC Update of 2024 covered stock compensation and other standards updates, filer status assessments and recent SEC/ PCAOB enforcement actions.
